Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the ...

Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday ​proposed withdrawing approval of Amgen's ...

Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc.

Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026.

Amgen doubles down in New Albany: expansion plus solar, CO2 refrigeration and EV chargers as it chases carbon neutrality.

In its upcoming report, Amgen (AMGN) is predicted by Wall Street analysts to post quarterly earnings of $4.73 per share, reflecting a decline of 3.5% compared to the same period last year. Revenues ...

Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years. Reese, ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...

US biotech major Amgen has announced the retirement of David Reese, executive vice president and chief technology officer, ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...